Press Releases

Article on Tubulis’ novel ADC conjugation technology P5 makes it to the cover of Chemical Science!

MUNICH, GERMANY, March 03, 2023 – We are very proud we made it on the cover of the latest issue of the Royal Society of Chemistry’s flagship journal Chemical Science! Our joint publication with Christian P.R. Hackenberger highlights the ability of our novel ADC conjugation technology P5 to create ADCs with a high drug-to-antibody-ratio (DAR) of 8 and an excellent in vivo pharmacokinetics profile. Both traits are very important for the development of next-generation ADCs with improved efficacy and safety profile to provide new therapeutic options for cancer patients.

Read the full scientific paper here.

Thanks to Barth van Rossum for designing the Cover.


For Tubulis
Dominik Schumacher,
CEO & Co-Founder
Phone: +49 175 800 5594

Media Requests for Tubulis
Trophic Communications
Stephanie May or Marie Weickert
Phone: + 49 171 185 5682

Share Article

More Press Releases

Tubulis partners TUB-010, its CD30-targeting IND-ready ADC, with Oncoteq

Tubulis publishes article in Molecular Cancer Therapeutics on advantages of its proprietary P5/Tubutecan platform

Tubulis Announces Strategic License Agreement with Bristol Myers Squibb to Develop Next Generation ADCs for the Treatment of Cancer Patients